Cargando…

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers

OBJECTIVES: We aimed to examine clinical data and baseline blood test results as potential predictive biomarkers for benefit from nivolumab, in advanced non-small cell lung cancer patients (NSCLC). MATERIALS AND METHODS: A chart review was performed of 108 advanced NSCLC patients who commenced treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daher, Sameh, Lawrence, Yaacov R., Dudnik, Elizabeth, Hanovich, Ekaterina, Urban, Damien, Peled, Nir, Navon, Rossie, Leibowitz, Raya, Hammerman, Ariel, Battat, Erez, Gottfried, Teodor, Onn, Amir, Bar, Jair
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335163/ https://www.ncbi.nlm.nih.gov/pubmed/34367942 http://dx.doi.org/10.3389/fonc.2021.625668

Ejemplares similares

Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients
por: Magri, Valentina, et al.
Publicado: (2019)

Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
por: Onn, Amir, et al.
Publicado: (2021)

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Self-reported sleep quality as prognostic for survival in lung cancer patients
por: Gottfried, Teodor, et al.
Publicado: (2020)

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone
por: Saad, Akram, et al.
Publicado: (2022)

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report
por: Sarfaty, Michal, et al.
Publicado: (2017)

Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades
por: Bar, Jair, et al.
Publicado: (2021)

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2(nd)/3(rd)-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
por: Raphael, Ari, et al.
Publicado: (2022)

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing
por: Sehayek, Or, et al.
Publicado: (2022)

Effects of EGFR driver mutations on pathologic regression in resectable locally advanced non-small cell lung cancer treated with neoadjuvant chemoradiation and completion surgery
por: Appel, Sarit, et al.
Publicado: (2023)

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
por: Rouvinov, Keren, et al.
Publicado: (2019)

A Novel Urine Test Biosensor Platform for Early Lung Cancer Detection
por: Wiesel, Ory, et al.
Publicado: (2023)

New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer
por: Nisman, Benjamin, et al.
Publicado: (2016)

Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor
por: Zehavi, Liron, et al.
Publicado: (2012)

Predicting brain metastasis in early stage non-small cell lung cancer patients by gene expression profiling
por: Kamer, Iris, et al.
Publicado: (2020)

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
por: Icht, Oded, et al.
Publicado: (2023)

Long term follow-up of EGFR mutated NSCLC cases
por: Rennert, Gad, et al.
Publicado: (2020)

FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
por: Raphael, Ari, et al.
Publicado: (2022)

Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?
por: Saad, Akram, et al.
Publicado: (2017)

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit
por: Haberman, Yael, et al.
Publicado: (2023)

Mesencephalic astrocyte-derived neurotrophic factor is secreted from interferon-γ–activated tumor cells through ER calcium depletion
por: Peled, Michael, et al.
Publicado: (2021)

Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival
por: Suidan, Anna May, et al.
Publicado: (2019)

Programmed death-ligand 1 expression discrepancy between primary tumor and metastatic lymph nodes in non-small cell lung cancer
por: Kian, Waleed, et al.
Publicado: (2020)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program
por: Illini, Oliver, et al.
Publicado: (2022)

A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker
por: Gillis, Avi, et al.
Publicado: (2021)

Intensity‐modulated radiotherapy is a safe and effective treatment for localized malignant pleural mesothelioma
por: Simon, Michael, et al.
Publicado: (2018)

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
por: Goldstein, Iris M, et al.
Publicado: (2020)

Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Shalata, Walid, et al.
Publicado: (2023)

BRCA mutations detected by tumour next-generation sequencing in non-small cell lung cancer: impact on response to therapy and disease course
por: Tschernichovsky, Roi, et al.
Publicado: (2023)

Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
por: Arbel, Ronen, et al.
Publicado: (2022)

Functional analysis of ADARs in planarians supports a bilaterian ancestral role in suppressing double-stranded RNA-response
por: Bar Yaacov, Dan
Publicado: (2022)

Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT)
por: Addeo, Alfredo, et al.
Publicado: (2021)

Social Media Use and Well-being With Bipolar Disorder During the COVID-19 Pandemic: Path Analysis
por: Pollock Star, Ariel, et al.
Publicado: (2022)

Real-world effectiveness of a single dose of mpox vaccine in males
por: Wolff Sagy, Yael, et al.
Publicado: (2023)

Change in Hospitalizations and 30-Day Mortality of Patients With Acute Myocardial Infarction During the First COVID-19 Lockdown – A Pure Social Isolation Effect?
por: Lavie, Gil, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
por: Gal, Omer, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v8mvpg8k8i0jgm4t3l7odbe95o